ID   MCF-7/F
AC   CVCL_C5RU
DR   Wikidata; Q116049772
RX   PubMed=17016657;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   PubMed=17016657; DOI=10.3892/ijo.29.5.1237;
RA   Liu H., Cheng D., Weichel A.K., Osipo C., Wing L.K., Chen B.,
RA   Louis T.E., Jordan V.C.;
RT   "Cooperative effect of gefitinib and fumitremorgin c on cell growth
RT   and chemosensitivity in estrogen receptor alpha negative
RT   fulvestrant-resistant MCF-7 cells.";
RL   Int. J. Oncol. 29:1237-1246(2006).
//